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Introduction 
Multiple Sclerosis (MS) is an immunologically controlled, inflammatory, demyelinating 
disease, characterized by destruction of the white matter (myelin) of the Central Nervous 
System (CNS), leading to serious medical conditions and paralysis [1]. It is believed that MS is 
an autoimmune disease in which T-cell response is directed to the immunodominant epitopes of 
the myelin proteins. T-cell response is triggered by the formation of the trimolecular complex 
between the Major Histocompatibility Complex (MHC), known as Human Leukocyte Antigen 
(HLA) in humans, the immunodominant epitopes of myelin proteins and the T-cell receptor 
(TCR) [2]. In this study, the interactions that occur during the creation of the trimolecular 
complex (pdb file: 1YMM) have been identified. The conformational characteristics that are 
essential for the disease induction and the rational design of non-peptide inhibitors were 
proposed. The MBP83-96 epitope (Glu83AsnProValValHisPhePheLysAsnIleValThrPro96) was 
specifically chosen for the rational design because it is identified as one of the main 
immunodominant epitope in MS patients [3, 4]. The aim of this study was the rational design 
and synthesis of non-peptide mimetics with the ability to mimic the immunodominant 83-96 
epitope of MBP, to block the formation of the trimolecular complex and therefore the T cell 
activation. The designed non-peptide mimetics aim to bind to the TCR, prevent and stop the 
formation of the trimolecular complex and the further stimulation and proliferation of the 
encephalitogenic T-cells [5, 6].  
 
Results and Discussion 
The design of non peptide molecules was achieved by using “structure based” in combination with “ligand based” drug design. The MOE software in a Linux environment was used for the 
simulation studies while the pharmacophore search was carried out in the zinc-drug alike 
database. The main steps of the rational design are: i) crustal structure of the HLA/peptide/TCR 
complex (1YMM), ii) recognition of the key pharmacophore groups, iii) development of 
pharmacophore model, iv) hit visualization, optimization, v) final molecules and vi) synthesis 
 
Fig. 1. Synthetic procedure of the pyrrole analogue using the pyrrole-3-carboxylic 
acid starting material. 
 and biological evaluation. The amino acids Val87 and Phe90 of the MBP83-96 are the main anchors 
in the hydrophobic pockets P1 and P4 of the HLA while secondary anchors have been 
recognized the amino acid Asn92, Ile93 and Thr95 that interact with the P6, P7 and P9 pockets. 
The binding of the TCR to the peptide-HLA complex was mainly determined by the 
arrangement of the side chain of the Val86, His88, Phe89 and Lys91 that interact with the P-1, P2, 
P3 and P5 pockets of the TCR [2,4,5]. The pockets P2 and P3 were selected for the creation of 
the pharmacophore model (Table 1) because they are hydrophobic and aromatic and the binding 
of TCR on the HLA-Peptide occurs diagonally from the N terminal of the peptide antigen. 330 
hits of zinc database, satisfied the conformational characteristics of model and after the 
visualization and docking studies of the 330 hits on the TCR, one of them was selected (lead 
molecule) for further optimization. The optimization includes the next steps: i) extension: 
addition of functional groups to increase the interaction, ii) simplification: removal of groups 
that are not a part of the pharmacophore groups and iii) rigidification: for flexible molecules, the 
number of available conformations is reduced while the bioactive conformation is conserved. 
The optimization was performed using the LigX of the MOE software following by docking 
studies. The final molecules have the pyrrole moiety as the main template, are N substituted 
with the benzyl group (alone or substituted with a negative charged group) and are substituted at 
position 2 or 3 of the pyrrole with guanidine. The proposed non-peptide mimetic molecules 
have the following characteristics: i) they are placed deeply on the TCR pockets, ii) they seem 
to interact strongly with the TCR increasing the binding sites with the TCR, iii) they reveal pi-
stacking interactions, iii) they are according to Lipinski’s “Rule of Five” for pharmaceutical 
molecules, iv) they could be absorbed in vivo, v) they could be potential bioactive molecules, vi) 
they could be synthesized simply based on retro-synthetic analysis (Figure 1).  
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Table 1. The MBP83-96 key residues for interaction with HLA and TCR that are used for the 
development of the pharmacophore model. 
Pharmacophore Groups Features 
F1 (1,4 Å) Aro Aromatic Ring (His88) 
F2 (1,5 Å) Hyd Hydrophobic isopropyl- group (Val86) 
F3 (1,4 Å) Aro Aromatic ring (Phe89) 
F4 (1,6 Å) Cat 
Cation and donor (the Ν terminal of Pro85 
interacts with Tyr58 of the TCR β-chain) 
V1 (1,8 Å) 
Volume exclusion (interaction of Val87 
 
with 
the HLA receptor) 
V2 (1,5 Å) 
Volume exclusion (interaction of Phe90
 
 with 
the HLA receptor) 
 
